EyeGate Pharma is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product candidate, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues though the Company’s proprietary EyeGate® II Delivery System. The Company completed a Phase III pivotal trial of EGP-437 for the treatment of non-infectious anterior uveitis, and plans to initiate a confirmatory Phase III trial.

Stock Quote

EYEG (Common Stock)
  • ExchangeNASDAQ
  • Price$2.19
  • Change-0.05
  • Volume143355
  • Data as ofMar 24 2017 4:00PM